ST8Sia III CRISPR Activation Plasmid (h): sc-407120-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ST8Sia III CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- ST8Sia III CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by ST8Sia III CRISPR Activation Plasmid (h) and ST8Sia III CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ST8SIA3 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ST8Sia III CRISPR Activation Plasmid (h) | sc-407120-ACT | 20 µg | $397.00 | |||
ST8Sia III CRISPR Activation Plasmid (h2) | sc-407120-ACT-2 | 20 µg | $397.00 |
ST8SIA3 encodes ST8Sia III, a Golgi-resident α2,8-sialyltransferase that elongates sialic acid chains on glycoproteins and glycolipids to generate polysialylated glycans. By remodeling cell-surface and extracellular glycosylation, ST8Sia III influences membrane organization, receptor interactions, and cell–cell communication, with downstream effects on adhesion, migration, and differentiation programs. Altered sialylation signatures are frequently observed in cancer and immune dysregulation, and ST8SIA3 expression has been linked to changes in tumor cell invasiveness and signaling phenotypes. This gene is therefore relevant for studies of glycosylation-dependent regulation of developmental pathways and disease-associated cell-state transitions.
ST8Sia III CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ST8SIA3 expression without altering the underlying DNA sequence.
ST8Sia III CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ST8SIA3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ST8SIA3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous ST8Sia III expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ST8SIA3 locus and enabling the study of ST8Sia III-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of ST8Sia III pathway restoration in tumor cells with silenced or reduced ST8SIA3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.